Skip to main content
. 2017 Aug 28;24(1):1191–1203. doi: 10.1080/10717544.2017.1365395

Figure 2.

Figure 2.

Biodistribution of intravenous or inhaled administration of yuanhuacine/MNPs accumulation in the (a) liver, (b) kidney, (c) spleen, (d) reproductive, and (e) lung at different time points with a yuanhuacine dose of 100 μg/kg (n = 4). *p < .05, **p < .01 versus intravenous group.